Supplemental Digital Content 2 – Table 1. Ratio of third trimester to postpartum pharmacokinetic parameter geometric mean (90% CI) ratios

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **Atazanavir without Tenofovir****n=13** | **Atazanavir with Tenofovir****n=19** |
| **Atazanvir** | AUC0-24(mcg\*hr/mL)  |  0.70 (0.55 – 0.88) | 0.66 (0.52 – 0.85)  |
| Cpre-dose (mcg/mL)  | 0.33 (0.16 – 0.70) \* | 0.61 (0.44 – 0.85)  |
| Cmax (mcg/mL)  | 0.86 (0.68 – 1.08) | 0.69 (0.53 – 0.91) |
| Tmax (hr)  | 1.2 (0.77 – 1.93) | 0.93 (0.69 – 1.24) |
| C24h (mcg/mL)  | 0.51 (0.37 – 0.72) \* | 0.65 (0.54 – 0.77) \* |
| Cmin (mcg/mL)  | 0.35 (0.17 – 0.76) \* | 0.63 (0.49 – 0.80)  |
| CL/F (L/hr)  | 1.43 (1.13 – 1.81) | 1.51 (1.18 – 1.93) |
| Vd/F (L)  | 0.84 (0.73 – 0.97) | 1.26 (0.84 – 1.90) |
| t½ (hr)  | 0.59 (0.48 – 0.73) \* | 0.74 (0.56 – 0.97) |

\* 90% CI fall completely outside of the range, 0.8 – 1.25, indicating the parameters are different;

CI = confidence interval